A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-26 and is reviewed periodically as new material appears.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Prior to 1985, W. R. Grace operated a retail division. Among its brands were Orchard Supply Hardware and Home Centers West (sold to Wickes Companies in 1986), Handy City home improvement stores, Home Quarters Warehouse, J. B. Robinson Jewelers, Sheplers Western Wear, and Herman's World of Sporting Goods which it had acquired in 1970. These were sold to various buyers in 1985. In 1986, Grace announced the sales of its 56 percent stake in Herman's Sporting Goods to the Dee Corporation for $227 million.
According to the official website of CBSE, there are 28 government- and private-affiliated schools in various countries outside India. The reason for their establishment is mainly to serve the Indian community abroad, or at least children or relatives of Indian diplomats. In countries where the population of Indian nationals surpasses the country's native population or where they form a substantial share of the population, like Saudi Arabia, the United Arab Emirates, Oman, Qatar, Bahrain, etc., Indian embassies have established CBSE schools and allowed Indians or locals to establish private CBSE schools serving the needs of Indians in those particular countries. But in countries where Indians do not reside, Indian diplomatic missions have established schools, such as those in Russia and Iran, which mainly serve the children of diplomats.
== Structure == Like other amino acids (not as a residue of a protein), cysteine exists as a zwitterion. Cysteine has l chirality in the older d/l notation based on homology to d- and l-glyceraldehyde. In the newer R/S system of designating chirality, based on the atomic numbers of atoms near the asymmetric carbon, cysteine (and selenocysteine) have R chirality, because of the presence of sulfur (or selenium) as a second neighbor to the asymmetric carbon atom. The remaining chiral amino acids, having lighter atoms in that position, have S chirality. Replacing sulfur with selenium gives selenocysteine.
Sources: en.wikipedia.org
Germany is a federation comprising sixteen constituent states referred to as Länder, thirteen of which are so-called "area-states" (Flächenländer). Two states, Berlin and Hamburg, are city-states (Stadtstaaten), in which there is no separation between state government and local administration. The state of Bremen, though officially also called a Stadtstaat, consists of the cities of Bremen, for which the state government also serves as the municipal administration, and the exclave of Bremerhaven. Each state (Land) has its own constitution and is largely autonomous in its organisation. As of 2017, Germany is divided into 401 districts (Kreise) at a municipal level; these consist of 294 rural districts and 107 urban districts.
If a strut of nasal-septum cartilage proves too weak, then a rib cartilage strut can be applied to provide the adequate nasal support; afterwards, the strut is covered with onlay grafts. Absent alar cartilages can be replaced using all of the conchal cartilage from both ears; two strips, each 10 mm wide, are harvested from the antihelical fold, and then are applied as replacement alar wings. The surgeon attaches them to the anterior nasal spine, and to each side of the (pear-shaped) pyriform aperture; the remainder of the harvested conchal cartilage is applied as onlay grafts to augment the nasal tip. A nasal-tip lining defect is unusual, because of its midline location; yet, the reconstruction is with an anteriorly based septal mucosal flap that is rotated into place to provide adequate coverage and correction of the nasal lining defect. Vertical lobule division (VLD) is a common technique for nasal tip refinement, which involves the medial crural angle and the lateral crural angle. (d) Alar lobule defect The appropriate surgical management of an alar lobule defect depends upon the dimensions (length, width, depth) of the wound. Anatomically, the nasal skin and the underlying soft tissues of the alar lobule form a semi-rigid aesthetic subunit that forms the graceful curve of the alar rim, and provides unobstructed airflow through the nostrils, the anterior nares.
=== BLAST networking technology === Networks based on DASH7 differ from typical wire-line and wireless networks utilizing a "session". DASH7 networks serve applications in which low power usage is essential and data transmission is typically much slower and/or sporadic, like basic telemetry. Thus, instead of replicating a wire-line "session", DASH7 was designed with the concept of B.L.A.S.T.:
Sources: en.wikipedia.org
=== Mary Smith === Mary Smith (Melissa Knatchbull) is Diana's mother and Rishi's mother-in-law. After Diana's murder, Mary takes custody of Rishi and Diana's baby son, Hugo, granting Rishi limited visitation under her supervision. She later meets Rishi to sign her petition to change Hugo's last name to Smith, making it easier for the family to travel with him, in exchange for allowing Rishi continued visitation. She remains outwardly cordial with Rishi, asserting that her Christian faith supersedes her anger towards him.
as a function of wavelength will yield a superposition of the effects of absorption and scattering. Because the absorption portion is more distinct and tends to ride on a background of the scatter portion, it is often used to identify and quantify the absorbing species. Consequently, this is often referred to as absorption spectroscopy, and the plotted quantity is called "absorbance", symbolized as
Ververi–Brady syndrome (VERBAS) is a rare inherited disorder of unknown prevalence usually caused by a heterozygous mutation in the QRICH1 gene. This mutation has been observed as both inherited as well as de novo in patients. Ververi–Brady syndrome was first described by Athina Ververi in 2018. The syndrome features a broad spectrum of symptoms, but all patients generally have mild chondrodysplasia, developmental delays, and mild dysmorphic facial features such as prominent nose. As of January 2026, here have only been 42 reported cases.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.